
News|Articles|August 1, 2008
August 2008 Oncology News International
Advertisement
Cover Story
- High cost of biologics takes a toll on hem/onc practices
- FDA cracks down on counterfeit cancer cure products
DEPARTMENTS
Focus on Breast Cancer
- Mastectomy rates for early breast cancer are on the upswing at one Mayo Clinic
- Is breast MRI primed for widespread use as a high-risk screening tool?
- Vantage Point: Risk factors will guide the imaging paradigm
Focus on Lung Cancer
- Anti-IGF-1R antibody plus chemo active in advanced non-small-cell lung cancer
News & Analysis
- Oncologic drug safety: Separating fact from fiction
Focus on Prostate Cancer
- Dual antiangiogenic therapy plus chemo is active in advanced prostate cancer
Advertisement
Related Content
Advertisement

ByDiana I. Lüftner,Rupert Bartsch,Urs Breitenstein,Christian Jackisch,Volkmar Mueller,Marcus Schmidt,Marija Balic,Gabriel Rinnerthaler,Khalil Zaman,Michael Schwitter,Denise Wrobel,Dagmar Guth,Matthias Zaiss,Jürgen Terhaag,Lidia Perlova-Griff,Rachel Wuerstlein,Timo Schinköthe,Corinne Vannier,Nadia Harbeck, MD, PhD

110 Randomized Phase II Trial Evaluating Three Anti-diarrheal Prophylaxis Strategies in Patients (pts) with HER2+/HR+ Early Breast Cancer (EBC) Treated with Extended Adjuvant Neratinib (Dianer Geicam/2018-06)
ByJ. Gil-Gil,M. Ruíz-Borrego,E. Carrasco,Y. Izarzugaza,C. Martínez-Vila,E. Galve,B. López-Barajas,E. Adrover,T. Silovski,M. Valero-Arbizu,Á. Guerrero-Zotano,S. González-Santiago,M. Echarri,A. Cano-Jiménez,A. Vethencourt-Casado,M. De Laurentis,C. Bueno-Muiño,B. Adamo,R. Andrés,C. Villanueva,F. Rojo,M. Casas,P. Wilson,J. Suissa,V. Adams,M. Martin





















